Abstract-␤-Adrenoceptors contribute to hypertension in spite of the fact that ␤-adrenoceptor agonists lower blood pressure. We aimed to differentiate between these functions and to identify differences between spontaneously hypertensive and normotensive rats. ␤-Adrenoceptor antagonists with different subtype selectivity or the ability to cross the blood-brain barrier were used to demonstrate ␤-adrenoceptor involvement in resting blood pressure and the response to tyramine-induced peripheral norepinephrine release. The centrally acting propranolol (␤ 1ϩ2[ϩ3] ), CGP20712A (␤ 1 ), ICI-118551 (␤ 2 ), and SR59230A (␤ 3 ), as well as peripherally restricted nadolol (␤ 1ϩ2 ) and atenolol (␤ 1 ), were administered intravenously, separately, or in combinations. Blood pressure, cardiac output, heart rate, total peripheral vascular resistance, and plasma catecholamine concentrations were evaluated. ␤-Adrenoceptor antagonists had little effect on cardiovascular baselines in normotensive rats. In hypertensive rats, antagonist-induced hypotension paralleled reductions in resistance, except for atenolol, which reduced cardiac output. The resistance reduction involved primarily neuronal catecholamine, central ␤ 1 -adrenoceptors, and peripheral ␤ 2 -adrenoceptors. Tyramine induced a transient, prazosin-sensitive vascular resistance increase. Inhibition of nerve-activated, peripheral ␤ 1/3 -adrenoceptors enhanced this ␣ 1 -adrenoceptor-dependent vasoconstriction in normotensive but not hypertensive rats. In hypertensive rats, return to baseline was eliminated after inhibition of the central ␤ 1 -adrenoceptor, epinephrine release (acute adrenalectomy), and peripheral ␤ 2/3 -adrenoceptors. Adrenalectomy eliminated ␤-adrenoceptor-mediated vasodilation in hypertensive rats, and tyramine induced a prazosin-sensitive vasoconstriction, which was inhibited by combined blockade of central ␤ 1 -and peripheral ␤ 2 -adrenoceptors. In conclusion, nerve-activated ␤ 1 -and ␤ 3 -adrenoceptor-mediated vasodilation was not present in hypertensive rats, whereas epinephrine-activated ␤ 2 -and ␤ 3 -adrenoceptor-mediated vasodilation was upregulated. There was also a hypertensive, nerve-activated vasoconstrictory mechanism present in hypertensive rats, involving central ␤ 1 -and peripheral ␤ 2 -adrenoceptors combined. (Hypertension. 2010;55:1224-1230.)
T he adrenergic system is a prime controller of blood pressure (BP). The ␣-adrenoceptor (AR), composed of ␣ 1 -and ␣ 2 -subtypes, elicits constriction in vascular smooth muscle cells (VSMCs). 1 In addition, ␣ 2 -ARs limit adrenergic activity by preventing catecholamine release in the central nervous system, peripheral sympathetic nerves, and the adrenals. 1 ␤-ARs located on VSMCs may oppose an ␣-AR tension response by activating the adenylyl cAMP pathway. 2 ␤ 2 -ARs on endothelial cells may activate NO synthesis and induce vasodilation. 2, 3 Also, ␤ 3 -AR may induce endothelial NO-and VSMC cAMP-dependent vasodilation. 4 Deficiencies in ␤-AR-induced vasodilation may result in hypertension.
Other ␤-AR-dependent mechanisms may increase BP. Central ␤-ARs of both the ␤ 1 and ␤ 2 subtypes are involved in the pressor response to behavioral stress, 5 and peripheral, presynaptic ␤ 2 -ARs enhance norepinephrine release. 6 Presynaptic ␤ 2 -ARs have been suggested to be activated by epinephrine, coreleased with norepinephrine. 7 Moreover, ␤ 1 -ARs in the kidney may activate renin release 8 and, consequently, angiotensin II formation with vasoconstriction and norepinephrine release. 9 In addition, cardiac ␤ 1 -and ␤ 2 -ARs stimulate cardiac function and may elevate BP by increasing cardiac output (CO). Because ␤-AR antagonists have been used efficiently in the treatment of hypertension for almost half a century, ␤-ARs most likely play an important role in the development of hypertension. How they do so is still not fully understood.
We aimed to show how ␤-ARs influence BP homeostasis and how their function differs in spontaneously hypertensive rats (SHRs). We hypothesized that the role of ␤-AR could be revealed by the effect of ␤-AR antagonists on resting BP and on a provoked sympathetic response. Through this approach, we were able to differentiate between ␤-AR-mediated vasodilation and vasoconstriction and to reveal altered ␤-AR functions in SHRs.
Methods

Experimental Procedures
The experiments were approved by the institutional review committee and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Systolic BP, diastolic BP, mean arterial BP (MBP), heart rate (HR), stroke volume (SV), CO (ascending aorta flow), and total peripheral vascular resistance (TPVR) were monitored in Nembutal-anesthetized (70 to 75 mg/kg IP), artificially ventilated rats. A total of 207 SHRs and 173 normotensive controls (Wistar-Kyoto [WKY] ), all male and 12 to 14 weeks old, were included. High-resolution flow data were used to estimate inotropy, that is, time from onset of flow increase to maximum rise in flow (T F ). Please see the online Data Supplement at http://hyper.ahajournals.org for detailed description.
Control rats were pretreated with a sham injection containing vehicle (PBS, IV) and infused with tyramine (1.26 mol/min per kilogram, 217 L/min per kilogram, 15 minutes). 10 Tyramine stimulates norepinephrine release by reverse transport through the norepinephrine reuptake transporter in peripheral sympathetic nerves. To identify the influence of ␤-ARs on baseline and on the tyramine response, PBS was substituted with ␤-AR antagonist, alone, or in combination, which included centrally active propranolol (␤ 1ϩ2ϩ [3] , 44 mol/kg), CGP20712A (␤ 1 , 11 mol/kg), ICI-118551 (␤ 2, 1 mol/kg start doseϩ0.3 mol/kg per minute), and SR59230A (␤ 3 , 13.8 mol/kg), as well as the peripherally restricted nadolol (␤ 1ϩ2 , 8.5 mol/kg) and atenolol (␤ 1 , 5.6 mol/kg). Drug concentration was halved for CGP20712Aϩnadolol. Adrenal catecholamine contribution was identified by adrenalectomy (AdrX; Ϫ30 minutes) and that of neuronal transmitter release by reserpine (8 mol/kg IP, Ϫ48 and Ϫ24 hours). Please see the online Data Supplement for further details.
Statistical Analyses
Results are presented as meanϮSE. The effects of ␤-AR antagonists on baselines, on ⌬T F after pretreatment or tyramine, and on plasma catecholamine concentrations were evaluated first by overall tests (1-way ANOVA). When the presence of significant differences was indicated, the response in the experimental group was compared with that after PBS in corresponding controls or with other experimental groups, using 2-sample Student t tests and, in the presence of outliers, Kruskal-Wallis tests. The tyramine-response curves were evaluated using repeated-measures ANOVA and ANCOVA, first as overall tests, then between groups or in 1 group separately. When significant responses, group differences, and/or interactions were indicated, contrasts were used to locate significant responses and differences between groups, respectively, at specific times. The P value was for each step and all of the tests adjusted according to Bonferroni, except for the plasma catecholamine levels where PՅ0.05 was used.
Results
Effect of ␤-AR Antagonists on Cardiovascular Baselines
The effects of AdrX and reserpine on the response to propranolol and the TPVR-response to all of the ␤-AR antagonists are shown in Figures 1 and 2 , respectively. For changes in all of the cardiovascular parameters in response to the ␤-AR antagonist and changes in inotropy (⌬T F ), please see Table S1 and S2 in the online Data Supplement.
In WKY rats, the ␤-AR antagonists had little effect on resting MBP and TPVR, and none of the antagonists influenced resting CO. Only propranolol reduced HR and pro- longed T F but increased SV. The propranolol-induced bradycardia was eliminated after reserpineϩAdrX (P value not significant; data not shown) but not after reserpine or AdrX alone (Figure 1 ), suggesting that both neuronal and adrenal catecholamines supported resting HR. SR59230A abbreviated T F by Ϸ8%, with the same tendency after AdrX, demonstrating the presence of nerve-activated, negative inotropic ␤ 3 -AR in WKY rats. In SHRs, all of the ␤-AR antagonists except SR59230A (␤ 3 ) reduced baseline MBP. The hypotension was paralleled by reductions in TPVR, except after atenolol (peripheral ␤ 1 ), which reduced CO. The MBP and TPVR responses to propranolol were eliminated after reserpine but not AdrX (Figure 1 ), indicating that the antihypertensive effect of propranolol primarily involved neuronal catecholamines. This conclusion agreed with the idea that AdrX did not influence the TPVR response to the various ␤-AR antagonists, although the response was not statistically significant in all of the groups ( Figure 2 ). CGP20712A but not atenolol reduced TPVR, demonstrating involvement of a central ␤ 1 -AR vasoconstrictory component. A TPVR reduction after nadolol but not atenolol identified a peripheral, vasoconstrictory ␤ 2 -AR component. However, CGP20712Aϩnadolol had no effect on TPVR in AdrX SHRs, possibly because of the reduced drug concentrations necessary to prevent death from cardiac failure. All of the antagonists, except SR59230A, reduced resting HR in SHRs. AdrX and reserpine reduced the propranolol-induced bradycardia. SR59230A had no effect on resting T F in SHR.
Effect of ␤-AR Antagonists on the Cardiovascular Response to Tyramine
Please see Table S1 for cardiovascular baselines after pretreatment, that is, before tyramine. As documented previously, 10 tyramine infusion induced a sustained increase in MBP ( Figure 3 ). This pressor response was composed of a transient rise in TPVR, which declined after 3 to 4 minutes and returned to baseline levels ( Figure 4 ). The vasoconstriction was in both strains, also after AdrX, abolished by prazosin, showing that it depended on VSMC ␣ 1 -AR activation (please see Figure S2 ). There was also an immediate increase in HR ( Figure 5 ) and CO (please see Figure S3 ), which remained throughout the infusion period. Tyramine had no effect on SV ( Figure S4 ) but abbreviated T F by Ϸ30% in both strains (please see Table S2 ), indicating a positive inotropic effect.
The TPVR Response
In WKY rats, the initial TPVR peak response to tyramine was increased after all of the ␤-AR antagonists but in AdrX WKY rats only after atenolol and SR59230A (Figure 4 ). These results demonstrated that nerve-activated peripheral ␤ 1 -and ␤ 3 -AR, as well as ␤ 2 -AR, activated by epinephrine from the adrenals, counteracted the initial vasoconstrictory TPVR response to tyramine. TPVR at the end of the 15-minute infusion period was increased after all of the antagonists except atenolol and SR59230A in WKY rats but not AdrX WKY rats (Figure 4) . Thus, the late vasodilation, which returned TPVR to baseline, depended on central ␤ 1 -AR and peripheral ␤ 2 -AR, both probably involving adrenal catecholamine(s).
The initial TPVR peak response to tyramine was not influenced by any of the ␤-AR antagonists in SHRs ( Figure  4 ), in spite of some increase in striated muscle ␤-AR density in SHRs (Table S3 ). However, the subsequent return to baseline was prevented by all of the antagonists, except atenolol and CGP20712AϩICI-118551 ( Figure 4 ). AdrX prolonged the TPVR peak response (Pϭ0.0002), and ␤-AR antagonists did not prevent the return to baseline in AdrX SHRs ( Figure 4 ). These results showed that ␤-AR-mediated vasodilation did not oppose the immediate, ␣ 1 -AR-mediated vasoconstriction in SHRs but identified central ␤ 1 -AR, peripheral ␤ 2 -AR, and ␤ 3 -AR, all involving adrenal catecholamine(s), as contributors in returning TPVR to baseline.
In AdrX SHRs, the vasoconstrictory TPVR response to tyramine was totally eliminated by propranolol or CGPϩnadolol (P value not significant and PՅ0.005 at 4 minutes, 1-and 2-sample Student t tests, respectively) and reduced by CGP20712AϩICI-118551 (Pϭ0.001 and 0.0005, respectively) but not influenced by nadolol alone (Figure 4 ). These results demonstrated that, when ␤ 2 -AR-mediated va- CGP20712AϩICI-118551ϩSR59230A was given only to AdrX rats and CGP20712Aϩnadolol to AdrX SHRs. For effect of pretreatment and number of rats per group, please see Table S1 . Significant influence of ␤-AR antagonist at peak response (brackets left of curves) and at 15 minutes (brackets right of curves) was detected as indicated. *PՅBonferroni-adjusted P value, 2-sample Student t tests after curve evaluations (please see the Methods section).
sodilation had been eliminated by AdrX, tyramine induced an ␣ 1 -AR-mediated vasoconstrictory response, which was sensitive to combined inhibition of central ␤ 1 -AR and peripheral ␤ 2 -AR. Surprisingly, the return to baseline TPVR was not blocked in SHRs after CGP20712AϩICI-118551, although both antagonists alone and propranolol did. These observations were likely to indicate that CGP20712AϩICI-118551 eliminated ␤ 1 -/␤ 2 -AR vasoconstriction and allowed ␤ 3 -but not ␤ 2 -ARmediated vasodilation, whereas propranolol also inhibited ␤ 3 -AR-mediated vasodilation. 11
The Cardiac Response ␤-AR antagonists greatly influenced the cardiac response to tyramine. The tyramine-induced tachycardia ( Figure 5 ) was reduced or eliminated in WKY rats by all of the antagonists that contained a ␤ 1 -AR inhibitory component. The HR response to tyramine after ICI-118551 (␤ 2 ) alone was not different from that in the controls, but combinations of ␤ 1 -and ␤ 2 -AR blockade reduced ⌬HR more efficiently than ␤ 1 -AR inhibition alone (PϽ0.0001 for curve interaction; PՅ0.0354 at 15 minutes). This difference was not observed in AdrX WKY rats. SR59230A caused some reduction in the tyramine-induced tachycardia in WKY rats and AdrX WKY rats. These results showed that tyramine-induced tachycardia was predominantly mediated through postsynaptic, peripheral ␤ 1 -AR with some contribution from ␤ 3 -AR, but, in the presence of ␤ 1 -AR blockade, through peripheral ␤ 2 -AR, activated by epinephrine. Tyramine abbreviated T F also in AdrX WKY rats (Ϫ32.8Ϯ4%; PՅ0.004), indicating that neuronal catecholamine activated the positive inotropic response. The T F abbreviation was hampered after CGP20712AϩICI-118551, nadolol, and atenolol but not influenced by ICI-118551 or SR59230A (Table S2) , showing that the positive inotropy was mediated through peripheral ␤ 1 -AR, and that negative inotropic ␤ 3 -AR did not influence this response. Increased ⌬SV ( Figure S4 ) was followed by a reduced tachycardia and not positive inotropy. Except for a reduction in the SR59230A group, there was no difference in the tyramine-induced rise in CO in WKY, but all of the antagonists reduced ⌬CO in AdrX WKY rats ( Figure S3) .
In SHRs, all of the antagonists, except ICI-188551 and SR59230A, reduced the tyramine-induced tachycardia (Figure 5) , showing that peripheral ␤ 1 -AR mediated the HR response. The further reduction in ⌬HR after additional inhibition of ␤ 2 -AR was not as prominent as in WKY rats ( Figure 5 ). Thus, epinephrine-activated ␤ 2 -ARs were less important in tyramine-induced tachycardia in SHRs, and SR59230A (␤ 3 ) had no effect on the HR response to tyramine in SHRs or AdrX SHRs ( Figure 5 ). Like in WKY rats, the positive inotropic effect of tyramine (Table S2 ) was primarily mediated through peripheral ␤ 1 -AR, activated by sympathetic nerves. Some contribution from epinephrine-activated ␤ 2 -AR was detected, because ICI-118551 reduced ⌬T F in SHRs but not AdrX SHRs. Reduction in the inotropic response to tyramine was paralleled by a reduced ⌬SV only in CGP20712AϩICI-118551ϩSR59230A-treated AdrX SHRs. Otherwise, an augmented SV response to tyramine was paralleled by reductions in ⌬HR. In both WKY and SHRs, ␤-AR antagonist-dependent reductions in the tyramineinduced MBP response ( Figure 3 ) were paralleled by a lower ⌬CO ( Figure S3 ), whereas an elevated MBP response was paralleled by an increased ⌬TPVR (Figure 4 ).
Effect of ␤-AR Antagonists on Tyramine-Induced Catecholamine Release
Tyramine increased the plasma concentration of norepinephrine (Table) . The concentration at the end of the 15-minutes tyramine infusion period was higher (PՅ0.011) than in blood collected during the initial peak response in SHRs (Pϭ0.006) but not different in WKY rats (P value not significant). CGP20712A and ICI-118551 (PՅ0.002), but not propranolol, reduced tyramine-induced norepinephrine overflow in SHRs. These differences were not observed in AdrX SHRs. The concentration of norepinephrine was reduced in WKY rats after propranolol, CGP20712A (PՅ0.001), or ICI-118551 (Pϭ0.047) and after propranolol in AdrX WKY rats (PϽ0.001).
The concentration of epinephrine (Table) increased throughout the experiment in the time controls. This increase was less at the end of the 15-minute tyramine infusion period in WKY rats but not SHRs. The concentration of epinephrine was increased after propranolol in both strains and reduced after CGP20712A (␤ 1 ) in SHRs (PՅ0.037). Epinephrine was almost completely absent in plasma from AdrX rats.
Discussion
The present experiments demonstrated the role of ␤-AR in BP control, at rest and during a stimulated adrenergic response in anesthetized WKY rats and SHRs. The experiments identified the ␤-AR subtype involved, their peripheral or central localization, the source of the catecholamine responsible for their activation, the cardiovascular parameter that they influenced, and their effect on catecholamine release. Our experimental design also allowed us to differentiate between ␤-AR-mediated vasodilatory and vasoconstrictory mechanisms.
␤-AR-Mediated Vasodilation
Norepinephrine overflow to plasma remained elevated throughout the tyramine infusion period. The transient nature of the ␣ 1 -AR-mediated vasoconstrictory TPVR response to tyramine was, therefore, not explained by transmitter exhaustion but involved activation of a vasodilatory response. In WKY rats, this vasodilation was mediated through nerve-activated peripheral ␤ 1 -AR and ␤ 3 -AR, subsequently replaced by epinephrine-activated ␤ 2 -AR. All of the ␤-ARs may activate the VSMC cAMP pathway, and ␤ 2ϩ3 -AR may also activate endothelial NO synthesis. 2,3 VSMC ␤ 1 -ARs, unlike ␤ 2 -ARs, are located within the synapse, 12 compatible with the more important role of norepinephrine-activated ␤ 1 -AR early in the infusion period and the later elevation in the plasma epinephrine concentration. A role of NO was supported by our previous study showing endothelial NO to counteract the TPVR response to tyramine. 10 The peripheral ␤ 2 -AR-dependent vasodilation also involved a central ␤ 1 -AR component, possibly responsible for the secretion of epinephrine (discussed below). ␤ 2 -AR-induced vasodilation has also been demonstrated to counteract norepinephrine-induced forearm vasoconstriction in humans, and a reduced vasoconstriction in women compared with men was explained by an augmented ␤ 2 -AR-mediated vasodilation. 13 Epinephrine-activated ␤ 2 -ARs may also possibly explain why propranolol increased resting forearm vascular resistance in awake humans, 14 in contrast to no effect in our anesthetized WKY rats and a reduced TPVR in SHRs, where plasma epinephrine initially was virtually absent. Peripheral ␤ 1 -AR did not oppose the initial TPVR peak response in SHRs, nor did ␤ 1 -AR contribute to the return to baseline or influence baseline TPVR. Indeed, neuronal catecholamine(s) were not involved in ␤-AR-mediated vasodilation throughout the tyramine infusion period. These results agreed with studies on isolated aorta demonstrating impaired ␤ 1 -AR-induced relaxation in SHRs, as well as impaired ␤-AR function in human hypertension. 2, 15 The subsequent return to TPVR baseline in SHRs depended exclusively on a central ␤ 1 -AR component and epinephrine-activated VSMC/ endothelial ␤ 2ϩ3 -AR-mediated vasodilation. The absence of epinephrine in plasma collected during the peak response explained why ␤ 2ϩ3 -AR failed to ameliorate the initial norepinephrine-induced vasoconstriction. VSMC vasodilatory ␤ 2 -ARs are located remotely from the synaptic cleft and are, thus, accessible by circulating epinephrine, and they have a higher affinity for epinephrine than norepinephrine. 12 Endothelial ␤ 2 -and ␤ 3 -ARs will be even more easily accessed by circulating epinephrine. Because CGP20712A reduced the plasma epinephrine concentration, the central ␤ 1 -AR component may be responsible for adrenal epinephrine release.
Cardiac Performance
The tachycardia after tyramine-induced norepinephrine release was primarily mediated through postsynaptic ␤ 1 -AR in both strains. However, when these were blocked, epinephrine-activated ␤ 2 -AR mediated tyramine-induced tachycardia in WKY rats. The ability of adrenal catecholamine to replace the neuronally released transmitter was also observed for the effect of propranolol on resting HR in WKY rats. The coexistence of ␤ 1 -and ␤ 2 -ARs in the heart is now generally accepted, 16 with a 3:1 distribution in both strains (Table S3) . However, the ability of ␤ 2 -AR to replace ␤ 1 -AR-mediated tyramine-induced tachycardia was detected in SHRs only after AdrX. The reason for this difference was not clear, but ICI-118551 also reduced resting HR and T F in AdrX SHRs.
In resting WKY rats, SR59230A revealed a ␤ 3 -ARmediated, neuronally dependent, negative inotropic activity. ␤ 3 -AR did not influence the tyramine-induced, positive inotropy, which was primarily ␤ 1 -AR mediated in both strains, with some additional contribution from ␤ 2 -AR in SHRs. However, ␤ 3 -AR mediated part of the tyramine-induced tachycardia in WKY rats and AdrX WKY rats, compatible with positive chronotropic ␤ 3 -AR demonstrated previously in the rat atrium. 17 Effects because of negative inotropic or positive chronotropic ␤ 3 -AR were not detected in SHRs.
Reduced inotropy after the ␤-AR antagonist was paralleled in both strains by reduced chronotropy, showing a parallel stimulation pattern for these 2 functions. Still, changes in SV were reciprocal to ⌬HR, showing that the time for diastolic heart filling was the important factor in determining SV. HR rather than SV determined CO, because reductions in CO at rest or during stimulation were paralleled by bradycardia or reduced tyramine-induced tachycardia, respectively.
Catecholamine Release
Presynaptic control of norepinephrine release was likely to be superimposed on the tyramine-induced, nonexocytotic, norepinephrine reuptake transporter-mediated release. Thus, ICI-118551 (␤ 2 ) lowered tyramine-induced norepinephrine overflow but not the plasma epinephrine concentration in both strains, compatible with the known role of presynaptic ␤ 2 -AR to enhance exocytotic norepinephrine release. 6 Activation of the presynaptic, release-stimulating ␤ 2 -AR apparently depended primarily on epinephrine, because a significant ICI-118551-induced reduction in norepinephrine overflow was not detected in AdrX SHRs (WKY rats not tested). The inhibitory effect of CGP20712A (␤ 1 ) on epinephrine secretion in SHRs may, therefore, explain the concomitant reduced norepinephrine overflow. In WKY rats, CGP20712A had no effect on epinephrine secretion, because tyramine itself reduced epinephrine release. The latter was likely to result from a concomitant activation of ␣ 2C -AR in the adrenals, known to inhibit adrenal catecholamine secretion. 18 Preliminary data indicated this to occur in WKY rats but not SHRs, thus explaining why norepinephrine release continued to rise throughout the tyramine-infusion in SHRs but not WKY rats. However, CGP20712A reduced norepinephrine overflow also in WKY rats. It is, therefore, possible that central ␤ 1 -AR increased adrenergic activity not only in the adrenals but also in peripheral sympathetic nerves, thus promoting presynaptic events, which enhanced tyramineinduced norepinephrine reuptake transporter norepinephrine transport. This conclusion was supported by a role of central ␤ 1 -AR in stress-induced hypertension in the rat. 5 The importance of the control of norepinephrine release was demonstrated recently in humans, where family history of hypertension and genetic variations in proteins involved in presynaptic catecholamine synthesis, storage, and metabolism predicted the constrictory response to tyramine in dorsal hand veins. 19 Furthermore, ICI-118551 (␤ 2 ) reduced BP in moderately hypertensive patients. 20 
Perspectives
Atenolol and Hypertension
Of the ␤-AR antagonists presently tested, only atenolol reduced baseline MBP in SHRs by lowering CO and not TPVR. As in SHRs, elevated TPVR and low CO characterize the condition in essential hypertension in humans, and longterm use of atenolol did not normalize these hemodynamic changes. 21 Compatible with these observations, atenolol has been suggested to be useful in the treatment of angina, myocardial infarction, and heart failure, but its efficacy in hypertension has been questioned. 22 
␤-AR-Dependent TPVR Control and Hypertension
The failing ␤ 1 -AR-mediated counteraction of tyramineinduced vasoconstriction may represent a hypertensive drive in SHRs, although possibly not in humans, where isoprenaline-induced forearm vasodilation was primarily mediated through ␤ 2 -AR and NO synthesis. 23 However, it could
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not be excluded that the latter observation reflected a difference in the response to a circulating contra intrasynaptically released agonist. In spite of enhanced epinephrine secretion and subsequent augmented norepinephrine release in SHRs, epinephrine functioned as an antihypertensive agent by upregulating ␤ 2 -and ␤ 3 -AR-mediated vasodilation. As a consequence of the exclusive adrenal contribution, ␤-AR-mediated vasodilation was totally eliminated in AdrX SHRs, and, in AdrX SHRs, surprisingly, the tyramine-induced, ␣ 1 -AR-mediated vasoconstriction was blocked after combined inhibition of central ␤ 1 -AR and peripheral ␤ 2 -AR. A neural mechanism, also involving central ␤ 1 -AR and peripheral ␤ 2 -AR, upheld resting MBP and TPVR in SHRs but not in WKY rats, further indicating that these receptors contributed to the hypertensive condition. Although the central ␤ 1 -AR may activate peripheral sympathetic nerve activity, it may be speculated that the peripheral ␤ 2 -AR activated a mechanism that prevented norepinephrine-activated, ␤-AR-induced VSMC vasodilation but left epinephrine-activated endothelial ␤ 2 -and ␤ 3 -ARmediated NO synthesis intact. This assumption was supported by the fact that nerve-activated ␤-AR vasodilation was not detected at all in SHRs, whereas neural catecholamine release induced not only ␤ 1 -but also ␤ 3 -AR-mediated vasodilation in WKY rats. Additional studies are needed for a better understanding of this potentially hypertensive mechanism.
Conclusions
In SHRs, nerve-activated ␤ 1 -and ␤ 3 -AR-mediated vasodilation was not present. A failing ␤-AR-activated moderation of an ␣ 1 -AR-mediated vasoconstriction may lead to hypertension, although epinephrine-activated ␤ 2 -and ␤ 3 -AR-mediated vasodilation was upregulated in SHRs. Presynaptic stimulation of norepinephrine release was enhanced in SHRs, possibly because of failing control of adrenal epinephrine secretion. In addition, we detected in SHRs a vasoconstrictory, neural mechanism involving central ␤ 1 -AR and peripheral ␤ 2 -AR combined. Although this mechanism was not fully understood, it elevated resting TPVR and augmented ␣ 1 -AR-mediated vasoconstriction in SHRs. 
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Plasma catecholamine measurements
Arterial blood (1.5 ml) was sampled into tubes containing 35 l 0.2 mol/L glutathione with 0.2 mol/L ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA) (4 o C). Plasma was stored at -80 °C until catecholamine concentrations were measured as previously described.
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Density of β-AR in skeletal muscle, kidney and heart
The density of surface -AR in the soleus and epitrochlearis muscles, kidney and heart from 6 WKY and 6 SHR was determined by their ability to bind the hydrophilic, nonselective β-AR ligand (-)- [5,7- 3 H]CGP-12177 (36.00 Ci/mmol). 14 In brief, biopsies (15-20 mg wet weight) were incubated with 1 nmol/l (-)- [5,7- 3 H]CGP-12177 (New England Nuclear, Boston, MA, USA) at 4 C for 40-44 hrs during continuous shaking, and subsequently washed with buffer (1 hr, 4 o C) to remove unbound ligand. Non-specific binding was defined as binding in the presence of 10 mol/l timolol, and found to be less than 15 % (tested in the soleus muscle).
The use of ascending aorta flow as an indicator of changes in cardiac inotropy
Analyses of ascending aorta flow (F) was used to indicate changes in inotropy. In separate experiments (please see Supplemental Figure S1 ), we evaluated this method by comparing Fderived values with values obtained from simultaneous recordings of left ventricular pressure (P). Time from onset of P-increase to P max (T P ) has been demonstrated to be an indicator of inotropic activity. 15 The results will show that changes in the corresponding F-derived value (T F ) was a useful indicator of changes in inotropy (please see Supplemental Figure S1 and Table S2 ). Tables   Table S1 . The effect of β-AR antagonist on cardiovascular baselines, and resulting baselines after pre-treatment, i.e., prior to tyramine. Heart (fmol/mg wet weight) 5±0 4±2
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β-AR density was higher in SHR in the soleus muscle (P<0.001) but not in the other tissues. Displacement with the β 2 -antagonist ICI-118,551 showed the β 1 : β 2 subtype ratio in the heart to be 3:1 in both strains.
Online Supplement Figures
Figure S1 High resolution data (5000 points/2 sec), i.e., left ventricular pressure (P) and ascending aorta flow (F), were stored throughout the experiment when pressing an assigned key on the computer. The P-and F-data from all heart-beats within each 2-sec-period were averaged (solid lines). Onset of P-or F-increase was determined by the maximum of the third derivative (long dotted lines), and maximum rise in P or F (P max or F max ) by the maximum of the first derivative (short dotted lines). Time from onset of P-and F-increase to P max or F max (T P and T F , respectively) were calculated.
50-100 simultaneous recordings of P and F were sampled before and after start of a tyramineinfusion in 6 WKY. Correlations were detected between dP/dt max and dP/dt max /P (c=0.45±0.50, P=0.0012), and between dP/dt max /P and T P (c=-0.59±0.40, P=0.0417).
Correlations were also detected between T F and dP/dt max , dP/dt max /P or T P (c=-0.91±0.07, -0.39±0.51, P≤0.006 and c=0.59±0.36, P≤0.028, respectively). The tyramine-induced abbreviation of T P (ΔT P =-23±14%) did not differ from changes in T F (Δ T F =-24±8%).
Significant correlations between these parameters and end-diastolic P or HR were not detected. ΔT F was therefore used to indicate a change in inotropy. Please see also Table S2 for further discussion.
Figure S2
Supplemental Figure S2 . The effect of prazosin on the TPVR-response to tyramine. The α 1 -AR antagonist prazosin eliminated the tyramine-induced rise in TPVR. When curve evaluation, including all groups, then between corresponding groups treated with prazosin or PBS (P0.05), or each group separately (P0.025), had indicated the presence of significant responses or group differences and/or interactions, these were located at the peak-response and at 15 min (P0.025). Significant responses (* within symbol) and group differences (* between curves) were detected as indicated (P0.025).
Prazosin reduced baseline TPVR in SHR but not WKY (ΔTPVR=-0.4±0.1, -0.4±0.1, -3.6±0.8* and -1.7±0.2* mm Hg/ml/min in WKY, AdrX WKY, SHR and AdrX SHR, respectively, * -P0.0125 for two-sample Student's t-tests compared to the response to PBS in the controls). The resulting TPVR, i.e., TPVR prior to tyramine, was 1.5±0.2, 1.8±0.2, 4.6±0.3 and 3.3±0.1* mm Hg/ml/min, respectively.
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Figure S3
Supplemental Figure S3 . Effect of β-AR antagonists on the CO-response to tyramine. The rats were pre-treated with PBS or β-AR antagonists as indicated by symbol legends. For number of rats per group, effect of pre-treatment and resulting CO prior to tyramine please see Online Supplemental Table S1 . Significant differences between the groups treated with β-AR antagonist and the corresponding PBS-controls at 15 min were as indicated, i.e., P0.05 for two-sample Student's t-tests after curve-evaluations had indicated significant differences or interactions with Bonferroni-adjustment of the P-value.
